Physician profile
Jay E Bowen
NPI 1821025370
$5,677.10
in general payments reported to CMS, 2019-2025
35 companies · $587 in 2025
The $587 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $698 · 2021: $634 · 2022: $1,007 · 2023: $1,001 · 2024: $709 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $3.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.14 |
| Education | $3.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,036.00 | 2019-2025 | Relistor |
| Abbvie INC. | $747.10 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $599.69 | 2019-2025 | Xtampza |
| Seapearl East, INC | $517.00 | 2019 | |
| Protega Pharmaceutials INC | $287.83 | 2022-2025 | Roxybond |
| Azurity Pharmaceuticals, INC. | $250.88 | 2023-2025 | Horizant, Horizant |
| Medtronic, INC. | $232.69 | 2022-2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $230.72 | 2022 | |
| Allergan, INC. | $222.88 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $175.34 | 2020-2025 | Ztlido |
| Biodelivery Sciences International, INC. | $164.26 | 2019-2020 | |
| Pfizer INC. | $138.51 | 2019-2023 | |
| Pacira Therapeutics, INC. | $130.13 | 2019-2021 | |
| Ibsa Pharma INC. | $105.52 | 2020-2023 | Tirosint, Licart |
| Redhill Biopharma INC. | $90.51 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $70.38 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.36 | 2019-2021 | |
| Lilly USA, LLC | $66.82 | 2020-2022 | |
| Fidia Pharma USA INC. | $54.39 | 2020-2023 | Hymovis, Triluron |
| Depuy Synthes Sales INC. | $51.95 | 2022-2025 | Monovisc, Orthovisc |
| Virtus Pharmaceuticals LLC | $48.81 | 2021-2025 | Levorphanol Tartrate |
| Zimmer Biomet Holdings, INC. | $41.84 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Hikma Pharmaceuticals USA | $35.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $35.31 | 2022-2024 | Euflexxa |
| Electronic Waveform Lab, INC. | $29.72 | 2023-2024 | |
| Arteriocyte Medical Systems, INC. | $26.54 | 2023 | Magellan |
| Abbott Laboratories | $25.95 | 2023 | Proclaim |
| Orthogenrx INC. | $20.02 | 2021 | |
| Boston Scientific Corporation | $19.70 | 2019 | |
| Amgen INC. | $19.38 | 2022 | |
| Bioventus LLC | $18.77 | 2020 | |
| Nevro Corp. | $15.31 | 2023 | Senza |
| Merz Pharmaceuticals, LLC | $14.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.